{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:18:49Z","timestamp":1794385129882,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10871-0","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T08:05:46Z","timestamp":1744099546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bridging the gap: identifying barriers and strategies for widespread implementation of long-acting injectable antiretroviral therapy in Sub-Saharan Africa: a scoping review"],"prefix":"10.1186","volume":"25","author":[{"given":"Pierre","family":"Gashema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Gad","family":"Iradukunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Saramba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tumusime","family":"Musafiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Umuhoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ndahimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Ingabire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moise Mukire","family":"Ndoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Mutagoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Emil","family":"Mwikarago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nyirimigabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhayimpundu","family":"Ribakare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean de Dieu","family":"Harelimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enos","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tafadzwa","family":"Dzinamarira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude Mambo","family":"Muvunyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"10871_CR1","doi-asserted-by":"publisher","unstructured":"Berruti M, Riccardi N, Canetti D, Lo Caputo S, Taramasso L, Di Biagio A. Injectable Antiretroviral Drugs: Back to the Future, Viruses, 2021;13(2):228, https:\/\/doi.org\/10.3390\/v13020228","DOI":"10.3390\/v13020228"},{"key":"10871_CR2","unstructured":"Global HIV. & AIDS statistics \u2014 Fact sheet. Accessed: Jan. 20, 2025. Available: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"10871_CR3","doi-asserted-by":"publisher","unstructured":"Cooper SE, Rosenblatt J, Gulick RM. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., 2022;75(Suppl 4):S541\u2013S548, https:\/\/doi.org\/10.1093\/cid\/ciac716","DOI":"10.1093\/cid\/ciac716"},{"key":"10871_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/25787489.2019.1661696","volume":"20","author":"M Murray","year":"2019","unstructured":"Murray M, et al. Patient-reported tolerability and acceptability of cabotegravir\u2009+\u2009rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Res Clin Pract. 2019;20:4\u20135. https:\/\/doi.org\/10.1080\/25787489.2019.1661696","journal-title":"HIV Res Clin Pract"},{"key":"10871_CR5","doi-asserted-by":"publisher","first-page":"232595822110090","DOI":"10.1177\/23259582211009011","volume":"20","author":"KK Scarsi","year":"2021","unstructured":"Scarsi KK, Swindells S. The promise of improved adherence with Long-Acting antiretroviral therapy: what are the data?? J Int Assoc Provid AIDS Care. 2021;20:23259582211009011. https:\/\/doi.org\/10.1177\/23259582211009011","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10871_CR6","doi-asserted-by":"publisher","unstructured":"Durham SH, Chahine EB. Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection, Ann. Pharmacother., 2021;55(11):1397\u20131409, https:\/\/doi.org\/10.1177\/1060028021995586","DOI":"10.1177\/1060028021995586"},{"key":"10871_CR7","doi-asserted-by":"publisher","unstructured":"Gelhorn H et al. Mar., Patient and Physician Preferences for Regimen Attributes for the Treatment of HIV in the United States and Canada, J. Pers. Med., 2022;12(3):3, https:\/\/doi.org\/10.3390\/jpm12030334","DOI":"10.3390\/jpm12030334"},{"issue":"1","key":"10871_CR8","doi-asserted-by":"publisher","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","volume":"13","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, et al. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a phase II study of cabotegravir\u2009+\u2009rilpivirine (LATTE-2) in the united States and Spain. PLoS ONE. 2018;13(1):e0190487. https:\/\/doi.org\/10.1371\/journal.pone.0190487","journal-title":"PLoS ONE"},{"key":"10871_CR9","doi-asserted-by":"publisher","unstructured":"Zakumumpa H, Alinaitwe A, Kyomuhendo M, Nakazibwe B. Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda. BMC Infect Dis. Aug. 2024;24(1):876. https:\/\/doi.org\/10.1186\/s12879-024-09748-5","DOI":"10.1186\/s12879-024-09748-5"},{"key":"10871_CR10","doi-asserted-by":"publisher","unstructured":"Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. J Subst Abuse Treat. Oct. 2020;117:108058. https:\/\/doi.org\/10.1016\/j.jsat.2020.108058","DOI":"10.1016\/j.jsat.2020.108058"},{"key":"10871_CR11","doi-asserted-by":"publisher","unstructured":"Liu Y, et al. Significant insights from a National survey in China: PrEP awareness, willingness, uptake, and adherence among YMSM students. BMC Public Health. Apr. 2024;24(1):1009. https:\/\/doi.org\/10.1186\/s12889-024-18512-y","DOI":"10.1186\/s12889-024-18512-y"},{"key":"10871_CR12","doi-asserted-by":"publisher","unstructured":"Liu Y, et al. Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the croprep study: a cross-sectional online study. BMC Public Health. Dec. 2023;23:2494. https:\/\/doi.org\/10.1186\/s12889-023-17325-9","DOI":"10.1186\/s12889-023-17325-9"},{"key":"10871_CR13","doi-asserted-by":"publisher","unstructured":"Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach, BMC Med. Res. Methodol., 2018;18(1):143, https:\/\/doi.org\/10.1186\/s12874-018-0611-x","DOI":"10.1186\/s12874-018-0611-x"},{"key":"10871_CR14","doi-asserted-by":"publisher","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework, Int. J. Soc. Res. Methodol., 2005;8(1):19\u201332, https:\/\/doi.org\/10.1080\/1364557032000119616","DOI":"10.1080\/1364557032000119616"},{"key":"10871_CR15","doi-asserted-by":"publisher","unstructured":"Castor D, Meyers K, Allen S. The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment, Curr. Opin. HIV AIDS, 2020;15(1):73\u201380, https:\/\/doi.org\/10.1097\/COH.0000000000000601","DOI":"10.1097\/COH.0000000000000601"},{"key":"10871_CR16","doi-asserted-by":"publisher","unstructured":"Mantsios A, et al. She is the one who knows\u2019: A qualitative exploration of oral and injectable PrEP as part of a community empowerment approach to HIV prevention among female sex workers in the Dominican Republic and Tanzania. PLOS Glob Public Health. Sep. 2022;2(9):e0000981. https:\/\/doi.org\/10.1371\/journal.pgph.0000981","DOI":"10.1371\/journal.pgph.0000981"},{"issue":"6","key":"10871_CR17","doi-asserted-by":"publisher","first-page":"e0234666","DOI":"10.1371\/journal.pone.0234666","volume":"15","author":"D Kerrigan","year":"2020","unstructured":"Kerrigan D, et al. A dream come true\u2019: perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLoS ONE. 2020;15(6):e0234666. https:\/\/doi.org\/10.1371\/journal.pone.0234666","journal-title":"PLoS ONE"},{"key":"10871_CR18","doi-asserted-by":"publisher","unstructured":"Cheng C-Y, Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Terris-Prestholt F. Determinants of heterosexual Men\u2019s demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa. BMC Public Health. Jul. 2019;19(1):996. https:\/\/doi.org\/10.1186\/s12889-019-7276-1","DOI":"10.1186\/s12889-019-7276-1"},{"key":"10871_CR19","doi-asserted-by":"publisher","unstructured":"Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of Long-Acting products to transform the treatment and prevention of human immunodeficiency virus (HIV) in infants, children, and adolescents. Clin Infect Dis Off Publ Infect Dis Soc Am. Nov. 2022;75:S562\u201370. https:\/\/doi.org\/10.1093\/cid\/ciac754","DOI":"10.1093\/cid\/ciac754"},{"key":"10871_CR20","doi-asserted-by":"publisher","unstructured":"Jamieson L, et al. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. Dec. 2022;9(12):e857\u201367. https:\/\/doi.org\/10.1016\/S2352-3018(22)00251-X","DOI":"10.1016\/S2352-3018(22)00251-X"},{"key":"10871_CR21","doi-asserted-by":"publisher","unstructured":"Jespersen S, et al. HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options. AIDS Res Ther. Feb. 2020;17(1). https:\/\/doi.org\/10.1186\/s12981-020-0259-6","DOI":"10.1186\/s12981-020-0259-6"},{"key":"10871_CR22","doi-asserted-by":"publisher","unstructured":"MacCarthy S, Saya U, Samba C, Birungi J, Okoboi S, Linnemayr S. \u2018How am I going to live?\u2019: exploring barriers to ART adherence among adolescents and young adults living with HIV in Uganda, BMC Public Health, vol. 2018;18(1):1158, https:\/\/doi.org\/10.1186\/s12889-018-6048-7","DOI":"10.1186\/s12889-018-6048-7"},{"key":"10871_CR23","doi-asserted-by":"publisher","unstructured":"Toska E, Zhou S, Chen-Charles J, Gittings L, Operario D, Cluver L. Factors Associated with Preferences for Long-Acting Injectable Antiretroviral Therapy Among Adolescents and Young People Living with HIV in South Africa, AIDS Behav., 2023;27(7):2163\u20132175, https:\/\/doi.org\/10.1007\/s10461-022-03949-2","DOI":"10.1007\/s10461-022-03949-2"},{"key":"10871_CR24","doi-asserted-by":"publisher","unstructured":"Simoni JM, et al. Lighten this burden of Ours\u2019: acceptability and preferences regarding injectable antiretroviral treatment among adults and youth living with HIV in coastal Kenya. J Int Assoc Provid AIDS Care. Mar. 2021;20:23259582211000517. https:\/\/doi.org\/10.1177\/23259582211000517","DOI":"10.1177\/23259582211000517"},{"key":"10871_CR25","doi-asserted-by":"publisher","unstructured":"Mgodi NM, et al. Advancing the use of Long-Acting extended delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations. J Int AIDS Soc. Jul. 2023;26:e26115. https:\/\/doi.org\/10.1002\/jia2.26115. Suppl 2, no. Suppl 2.","DOI":"10.1002\/jia2.26115"},{"key":"10871_CR26","doi-asserted-by":"publisher","unstructured":"Moyo E, Murewanhema G, Musuka G, Dzinamarira T. Long-Acting injectable drugs for HIV-1 Pre-Exposure prophylaxis: considerations for Africa. Trop Med Infect Dis. Jul. 2022;7(8):154. https:\/\/doi.org\/10.3390\/tropicalmed7080154","DOI":"10.3390\/tropicalmed7080154"},{"key":"10871_CR27","doi-asserted-by":"publisher","unstructured":"Wara NJ, et al. Preferences and acceptability for long-acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya. J Int AIDS Soc. May 2023;26(5):e26088. https:\/\/doi.org\/10.1002\/jia2.26088","DOI":"10.1002\/jia2.26088"},{"key":"10871_CR28","doi-asserted-by":"publisher","unstructured":"Culhane J, et al. Modeling the health impact and cost threshold of long-acting ART for adolescents and young adults in Kenya. EClinicalMedicine. Aug. 2020;25:100453. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100453","DOI":"10.1016\/j.eclinm.2020.100453"},{"key":"10871_CR29","doi-asserted-by":"publisher","unstructured":"Reynolds Z, et al. Who\u2019s slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa. HIV Med. May 2022;23(5):474\u201384. https:\/\/doi.org\/10.1111\/hiv.13203","DOI":"10.1111\/hiv.13203"},{"key":"10871_CR30","doi-asserted-by":"publisher","unstructured":"Grimsrud A, et al. The importance of the \u2018how\u2019: the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment. J Int AIDS Soc. Jul. 2023;26:e26095. https:\/\/doi.org\/10.1002\/jia2.26095. Suppl 2, no. Suppl 2.","DOI":"10.1002\/jia2.26095"},{"key":"10871_CR31","doi-asserted-by":"publisher","unstructured":"Ogunbajo A, Tsai AC, Kanki PJ, Mayer KH. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa, AIDS Behav., 2022;26(7):2363\u20132375,, https:\/\/doi.org\/10.1007\/s10461-022-03575-y","DOI":"10.1007\/s10461-022-03575-y"},{"key":"10871_CR32","doi-asserted-by":"publisher","unstructured":"Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. Jul. 2008;8:265. https:\/\/doi.org\/10.1186\/1471-2458-8-265","DOI":"10.1186\/1471-2458-8-265"},{"key":"10871_CR33","doi-asserted-by":"publisher","unstructured":"Kanazawa JT, Saberi P, Sauceda JA, Dub\u00e9 K. The LAIs are coming! Implementation science considerations for Long-Acting injectable antiretroviral therapy in the united States: A scoping review. AIDS Res Hum Retroviruses. Feb. 2021;37(2):75\u201388. https:\/\/doi.org\/10.1089\/AID.2020.0126","DOI":"10.1089\/AID.2020.0126"},{"key":"10871_CR34","doi-asserted-by":"publisher","unstructured":"Koester KA, et al. Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives. Implement Sci Commun. Oct. 2023;4(1):128. https:\/\/doi.org\/10.1186\/s43058-023-00506-3","DOI":"10.1186\/s43058-023-00506-3"},{"key":"10871_CR35","doi-asserted-by":"publisher","first-page":"807446","DOI":"10.3389\/fphar.2021.807446","volume":"12","author":"A Ahmed","year":"2021","unstructured":"Ahmed A, et al. Barriers and enablers for adherence to antiretroviral therapy among people living with HIV\/AIDS in the era of COVID-19: A qualitative study from Pakistan. Front Pharmacol. 2021;12:807446. https:\/\/doi.org\/10.3389\/fphar.2021.807446","journal-title":"Front Pharmacol"},{"key":"10871_CR36","doi-asserted-by":"publisher","unstructured":"Audi C, et al. Facilitators and barriers to antiretroviral therapy adherence among HIV-positive adolescents living in Tanzania. BMC Public Health. Dec. 2021;21(1):2274. https:\/\/doi.org\/10.1186\/s12889-021-12323-1","DOI":"10.1186\/s12889-021-12323-1"},{"key":"10871_CR37","doi-asserted-by":"publisher","unstructured":"Hutahaean BSH, Stutterheim SE, Jonas KJ. Barriers and facilitators to HIV treatment adherence in Indonesia: perspectives of people living with HIV and HIV service providers. Trop Med Infect Dis. Feb. 2023;8(3):138. https:\/\/doi.org\/10.3390\/tropicalmed8030138","DOI":"10.3390\/tropicalmed8030138"},{"issue":"2","key":"10871_CR38","doi-asserted-by":"publisher","first-page":"e0262926","DOI":"10.1371\/journal.pone.0262926","volume":"17","author":"O Jolayemi","year":"2022","unstructured":"Jolayemi O, et al. Perspectives on Preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS ONE. 2022;17(2):e0262926. https:\/\/doi.org\/10.1371\/journal.pone.0262926","journal-title":"PLoS ONE"},{"key":"10871_CR39","doi-asserted-by":"publisher","unstructured":"Jolayemi O, et al. Perspectives on Preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS ONE. Feb. 2022;17(2):e0262926. https:\/\/doi.org\/10.1371\/journal.pone.0262926","DOI":"10.1371\/journal.pone.0262926"},{"key":"10871_CR40","doi-asserted-by":"publisher","unstructured":"Chandiwana NC et al. Dec., Impact of long-acting therapies on the global HIV epidemic, AIDS, 2021;35(2),:S137, https:\/\/doi.org\/10.1097\/QAD.0000000000003102","DOI":"10.1097\/QAD.0000000000003102"},{"key":"10871_CR41","doi-asserted-by":"publisher","unstructured":"Rostamzadeh R, Sabaghi M, Esmaili A. Evaluation of Cost-Effectiveness Criteria in Supply Chain Management: Case Study, Adv. Decis. Sci., 2013;1\u201311. https:\/\/doi.org\/10.1155\/2013\/873534","DOI":"10.1155\/2013\/873534"},{"issue":"1","key":"10871_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10461-022-03817-z","volume":"27","author":"GG Edwards","year":"2023","unstructured":"Edwards GG, et al. Long-Acting injectable therapy for people with HIV: looking ahead with lessons from psychiatry and addiction medicine. AIDS Behav. 2023;27(1):10\u201324. https:\/\/doi.org\/10.1007\/s10461-022-03817-z","journal-title":"AIDS Behav"},{"key":"10871_CR43","doi-asserted-by":"publisher","unstructured":"Christopoulos KA, et al. First demonstration project of Long-Acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic. Clin Infect Dis Off Publ Infect Dis Soc Am. Feb. 2023;76(3):e645\u201351. https:\/\/doi.org\/10.1093\/cid\/ciac631","DOI":"10.1093\/cid\/ciac631"},{"key":"10871_CR44","unstructured":"Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment: Current Opinion in HIV and AIDS, Accessed: Jan. 20, 2025. Available: https:\/\/journals.lww.com\/co-hivandaids\/fulltext\/2015\/07000\/long_acting_antiviral_agents_for_hiv_treatment.8.aspx"},{"key":"10871_CR45","doi-asserted-by":"publisher","unstructured":"Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection, J. Antimicrob. Chemother., 2022;77(2):290\u2013302, https:\/\/doi.org\/10.1093\/jac\/dkab324","DOI":"10.1093\/jac\/dkab324"},{"key":"10871_CR46","unstructured":"2023WADreport_en.pdf. Accessed: Jan. 20. 2025. Available: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2023WADreport_en.pdf"},{"key":"10871_CR47","doi-asserted-by":"publisher","unstructured":"Gilbert HN et al. Oct., How community ART delivery may improve HIV treatment outcomes: Qualitative inquiry into mechanisms of effect in a randomized trial of community-based ART initiation, monitoring and re-supply (DO ART) in South Africa and Uganda, J. Int. AIDS Soc., 2021;24(10):e25821, https:\/\/doi.org\/10.1002\/jia2.25821","DOI":"10.1002\/jia2.25821"},{"key":"10871_CR48","doi-asserted-by":"publisher","unstructured":"Lahuerta M et al. Feb., The Problem of Late ART initiation in Sub-Saharan Africa: A Transient Aspect of Scale-up or a Long-term Phenomenon? J. Health Care Poor Underserved, 2013;24(1):359\u2013383, https:\/\/doi.org\/10.1353\/hpu.2013.0014","DOI":"10.1353\/hpu.2013.0014"},{"key":"10871_CR49","doi-asserted-by":"publisher","unstructured":"Matza LS, Howell TA, Chounta V, van de Velde N. Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV, Qual. Life Res., 2023;32(2):531\u2013541, https:\/\/doi.org\/10.1007\/s11136-022-03290-0","DOI":"10.1007\/s11136-022-03290-0"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10871-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T08:05:48Z","timestamp":1744099548000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10871-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10871"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10871-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.21.24317714","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"476"}}